Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6886873 | 0.87 | KDM4E (0.44) | KDM4ELMNAESR1CHRM1SLC6A4 | |
| SCHEMBL6622514 | 0.87 | KDM4E (0.44) | KDM4ELMNAESR1CHRM1SLC6A4 | |
| SCHEMBL6623589 | 0.87 | KDM4E (0.40) | KDM4ELMNAESR1CHRM1SLC6A4 | |
| SCHEMBL6624707 | 0.86 | KDM4E (0.45) | KDM4ELMNAESR1CHRM1SLC6A4 | |
| SCHEMBL6773435 | 0.85 | KDM4E (0.43) | KDM4ELMNAESR1CHRM1SLC6A4 | |
| SCHEMBL6886246 | 0.85 | KDM4E (0.36) | KDM4ELMNAESR1CHRM1SLC6A4 | |
| SCHEMBL6623582 | 0.85 | FAP (0.31) | — | |
| SCHEMBL6770670 | 0.83 | KDM4E (0.41) | KDM4ELMNAESR1CHRM1SLC6A4 | |
| SCHEMBL6886812 | 0.82 | KDM4E (0.40) | KDM4ELMNAESR1CHRM1SLC6A4 | |
| SCHEMBL7722334 | 0.80 | KDM4E (0.37) | KDM4ELMNAESR1CHRM1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825187-B2 | CARBAPENEM DERIVATIVES SUBSTITUTED AT THE 2-POSITION WITH A SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP; USE AGAINST ANTIBIOTIC RESISTANT STAPHYLOCOCCUS AUREUS AND PSEUDOMONAS AERUGINOSA, ENTEROCOCCI AND INFLUENZA VIRUS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| EP-1251133-B1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-6680313-B2 | 1-HYDROXYETHYL-2(IMIDAZO(5,1B)THIAZOL-2-YL-1-CARBAPEN-2-EM-3-C CARBOXYLIC ACID OR SALT, EXCELLENT ANTIBIOTIC ACTIVITY AGAINST A WIDE SPECTRUM OF BACTERIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-01-20 | — | — | US | disclosed |
| US-20030027809-A1 | Novel carbapenum derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-02-06 | — | — | US | disclosed |
| US-20030022881-A1 | Novel carbapenem derivatives of quarternary salt type | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
| EP-1251134-A1 | NOVEL CARBAPENEM DERIVATIVES OF QUATERNARY SALT TYPE | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
| EP-1251133-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027809-A1 | Novel carbapenum derivatives | DHPS, DPEP1, OXA1L | KDM4E 720/4885LMNA 3002/4885ESR1 4621/4885 |
| US-20030022881-A1 | Novel carbapenem derivatives of quarternary salt type | DHPS, HDHD5, RRP15 | KDM4E 531/4885LMNA 2166/4885ESR1 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.